Navigation Links
NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
Date:6/1/2009

    - Results from a randomized Phase IIb trial reported at 2009 ASCO Annual
    Meeting -

MISSISSAUGA, ON, June 1 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that results from a randomized trial of nimotuzumab (aka BIOMAb/TheraCIM/h-R3) in patients with inoperable, locoregionally advanced Stage III/IVa head and neck cancer conducted by Reddy BK et al (Kidwai Memorial Institute of Oncology, Bangalore, India), were presented in a poster at the 2009 ASCO Annual Meeting. The trial demonstrates that the efficacy of nimotuzumab compares favorably to results reported for cetuximab, an EGFR-targeting antibody marketed as Erbitux(R), but that this efficacy was not accompanied by the severe toxicities reported in patients treated with cetuximab. The authors further conclude that this trial is the first randomized study in head and neck cancer to their knowledge that challenges the adopted tenet that the efficacy of EGFR inhibitors is linked to the toxicity of the class.

"These data are further evidence of the unsupported extrapolation to the class of the toxicity/benefit correlation in the marketed EGFR drugs. The trial data demonstrate that patients have the prospect of equivalent clinical benefit from nimotuzumab as from the rest of the class without the physical, emotional and financial costs that result from the numerous and severe toxicities of Erbitux(R) which are a consequence of the demonstrable inability of that drug to discriminate between healthy cells and tumor cells," said David Allan, Chairman and CEO of YM BioSciences. "We expect that, as the numerous randomized trials currently ongoing worldwide with nimotuzumab re
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
2. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
3. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
4. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
5. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL
6. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
7. NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING
8. NOTICE OF YM BIOSCIENCES CONFERENCE CALL TO DISCUSS PHASE II DATA FOR NIMOTUZUMAB IN METASTATIC COLORECTAL CANCER
9. YM BIOSCIENCES NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
10. YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER
11. YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014  CorMedix Inc. (NYSE MKT: CRMD), ... therapeutic products for the prevention and treatment of ... notice on July 18, 2014 from the NYSE ... the CorMedix plan to regain compliance with continued ... the NYSE-MKT is continuing the Company,s listing and ...
(Date:7/24/2014)... Mich. , July 24, 2014  Neogen Corporation ... that future forecasts of its potential revenue from new ... call to investors and analysts on July 22, 2014, ... by analysts regarding this research. "It was ... questions about the potential of a new type of ...
(Date:7/24/2014)... 24, 2014 The first part of ... in First in Human Studies” will cover comprehensive clinical ... decisions. , With increasing R&D costs and declining industry ... to maximize the knowledge collected in early Phase I/IIa ... success in late stage development. , Next, the presenters ...
(Date:7/24/2014)... , July 24, 2014   Cypher Genomics, ... the appointment of Adam Simpson as ... provides rapid and comprehensive annotation and interpretation of ... reporting. "Cypher,s technology has the potential ... by enhancing diagnostic accuracy, optimizing therapeutic approaches and ...
Breaking Biology Technology:CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3Neogen comments on SenesTech 2Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 3
... ORANGE, N.J., Oct. 18, 2011 Kessler Foundation announced ... Research Center as Director of the Human Performance and ... 2012. "The addition of Dr. Yue is ... physical and cognitive research aimed at improving rehabilitation for ...
... 18, 2011 /PRNewswire-Asia/ -- China Botanic Pharmaceutical Inc. (NYSE ... "Company"), a developer, manufacturer and distributor of botanical products, ... announced that the board increased the number of directors ... annual board meeting and appointed Mr. Zack Zibing Pan ...
... Oct. 18, 2011 Immune Design Corp. (IDC) announced ... the company as its new Chief Business Officer.  In ... years of pharmaceutical and biotechnology industry experience to lead ... advancing pipeline of novel therapeutic vaccines and immunotherapies for ...
Cached Biology Technology:Kessler Foundation Appoints New Director of Human Performance and Engineering Laboratory 2Kessler Foundation Appoints New Director of Human Performance and Engineering Laboratory 3China Botanic Appoints Zack Zibing Pan as an Independent Director and Chairman of its Audit Committee 2China Botanic Appoints Zack Zibing Pan as an Independent Director and Chairman of its Audit Committee 3Immune Design Corp. Appoints Guy F. Cipriani as Chief Business Officer 2
(Date:7/24/2014)... of 3.5 billion years of evolutionary trial and error, ... it may be reaching a tipping point. , In ... data published in Science , an international team ... animals is contributing to what appears to be the ... event. , Since 1500, more than 320 terrestrial vertebrates ...
(Date:7/24/2014)... own microbial terroir, meaning the microbial populations found on ... product, creating the final flavor according to research published ... Environmental Microbiology . This is the first time investigators ... , Many sake makers inoculate with both bacteria ... the University of California, Davis, but he and his ...
(Date:7/24/2014)... 2014(BRONX, NY)Researchers at Albert Einstein College of Medicine ... The Michael J. Fox Foundation for Parkinson,s Research to ... Parkinson,s disease. This drug discovery project will test chemical ... of developing a drug that acts on an underlying ... for Parkinson,s help many people manage their symptoms, we ...
Breaking Biology News(10 mins):Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3The microbes make the sake brewery 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3
... there is a serious influenza outbreak will do little to ... findings of a study conducted at the UK Health Protection ... Sometimes a new type of influeza virus appears that causes ... case for flu. This happened, for example, in 1918, when ...
... defined the collective genome of the human gut, or colon. ... make up a motley "microbiome" that allows humans to digest ... fiber. , In a study published in the June ... for Genomic Research (TIGR) and their colleagues describe and analyze ...
... spend $21 billion for HIV/AIDS research, treatment, prevention, and ... study published in the July 1 issue of The ... it is--and more so than previously thought. , The ... , MD, MSc and colleagues at Massachusetts General Hospital ...
Cached Biology News:Air travel and pandemic flu 2Gut reaction: Researchers define the colon's genome 2Gut reaction: Researchers define the colon's genome 3New study calculates millions of years saved in lives of AIDS patients 2
... TOPO Cloning Kits for Sequencing allow 5-minute cloning ... contain TOPO Cloning vectors with primer sites located ... PCR product insertion site. This minimizes the amount ... before reaching the sequence of your insert.vectors are ...
Blot Paper 7 x 8.5cm semi-dry western blots (order number RB-400)...
The product contains 10 ml Dynabeads Epoxy (4.5 m). Supplied at 4 x 10 8 beads/ml...
Request Info...
Biology Products: